Starting With Triple Therapy Including Exenatide vs Sequential Add-On for Type 2 Diabetes
Initial triple therapy including the GLP-1 drug exenatide provided superior glycemic and non-glycemic benefits compared to traditional sequential add-on approach in newly diagnosed type 2 diabetes.
Quick Facts
What This Study Found
Initial triple therapy including exenatide provided superior glycemic control and non-glycemic benefits (weight, blood pressure) compared to sequential add-on therapy in type 2 diabetes.
Key Numbers
29 patients received initial triple therapy. Both groups maintained good blood sugar control for 6 years. Specific cIMT and liver fat measurements were compared.
How They Did This
Comparative study of initial triple therapy (including exenatide) versus sequential add-on in patients with type 2 diabetes. Assessed HbA1c, body weight, blood pressure, and metabolic parameters.
Why This Research Matters
Delaying effective treatment allows diabetes to progressively damage beta cells. Starting with triple therapy including a GLP-1 drug may preserve beta cell function and achieve better long-term outcomes.
The Bigger Picture
The diabetes treatment paradigm is shifting from conservative, step-wise escalation to early aggressive combination therapy. Including GLP-1 drugs from the start leverages their multi-organ benefits (glycemic control, weight loss, cardiovascular protection) from day one.
What This Study Doesn't Tell Us
Study design and duration vary. Triple therapy is more complex and expensive. Patient adherence to three drugs from the start may be challenging. Long-term outcomes need confirmation.
Questions This Raises
- ?Does early triple therapy prevent long-term beta cell decline better than sequential approach?
- ?Which GLP-1 drug is optimal as a component of initial triple therapy?
- ?Is the added cost of triple therapy offset by better long-term outcomes?
Trust & Context
- Key Stat:
- Start aggressive Triple therapy including exenatide from diagnosis outperformed the traditional one-drug-at-a-time approach for diabetes
- Evidence Grade:
- Moderate evidence: comparative study showing triple therapy superiority, though long-term outcomes need confirmation.
- Study Age:
- Published in 2025. Supports the emerging paradigm of early aggressive combination therapy for diabetes.
- Original Title:
- Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT study.
- Published In:
- BMJ open diabetes research & care, 13(2) (2025)
- Authors:
- Abdul-Ghani, Muhammad, Puckett, Curtiss, Abdelgani, Siham, Merovci, Aurora, Lavrynenko, Olga, Adams, John, Triplitt, Curtis, DeFronzo, Ralph A
- Database ID:
- RPEP-09741
Evidence Hierarchy
Frequently Asked Questions
Should I start multiple diabetes drugs at once?
This study suggests starting with triple therapy including a GLP-1 drug provides better results than adding drugs one at a time. The advantage is faster blood sugar control, weight loss, and potentially better preservation of your insulin-producing cells.
Why not just start with one drug first?
Traditional step-wise treatment means your blood sugar stays elevated for months while drugs are added sequentially. During this time, high blood sugar continues to damage beta cells. Starting aggressively may prevent this progressive damage.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09741APA
Abdul-Ghani, Muhammad; Puckett, Curtiss; Abdelgani, Siham; Merovci, Aurora; Lavrynenko, Olga; Adams, John; Triplitt, Curtis; DeFronzo, Ralph A. (2025). Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT study.. BMJ open diabetes research & care, 13(2). https://doi.org/10.1136/bmjdrc-2025-004981
MLA
Abdul-Ghani, Muhammad, et al. "Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT study.." BMJ open diabetes research & care, 2025. https://doi.org/10.1136/bmjdrc-2025-004981
RethinkPeptides
RethinkPeptides Research Database. "Glycemic and non-glycemic benefits of initial triple therapy..." RPEP-09741. Retrieved from https://rethinkpeptides.com/research/abdul-ghani-2025-glycemic-and-nonglycemic-benefits
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.